| September 2 |
Shionogi & Co., Ltd. to Acquire Sciele Pharma, Inc. |
| September 2 |
Novartis Decides Not to Pursue Further Development of Aurograb |
| September 2 |
Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011 |
| September 2 |
ZymoGenetics Earns Milestone Payment for RECOTHROM European Filing |
| September 2 |
Value of Direct-to-Consumer Drug Advertising Oversold, Study Finds |
| September 2 |
America's Pharmaceutical Research Companies Respond to Hurricane Gustav's Landfall |
| September 2 |
Takeda and Affymax Provide Clinical Development Update for Hematide in Chemotherapy-Induced Anemia |
| September 2 |
HIV/AIDS Update - Updated Labeling for Norvir (ritonavir) Soft Capsule and Oral Solution |
| September 2 |
IVAX Diagnostics Reports Sale of Parent Company's Interest |
| September 3 |
Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company |
| September 3 |
Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs |
| September 3 |
GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza |
| September 3 |
Léger Survey Reports 84 Per Cent of Ontario Physicians Feel Patients May Be Addicted to Prescription Painkillers |
| September 3 |
Study: Teen Suicide Spike Was No Fluke |
| September 3 |
Merck and ZymoGenetics Restructure Partnership |
| September 3 |
Zentiva N.V. – Sanofi Offer Update |
| September 4 |
Wolters Kluwer Health Reaches Agreement to Acquire UpToDate |
| September 4 |
Merck Serono and Ablynx Enter Into an Agreement to Co-Discover and Co-Develop Nanobodies |
| September 4 |
FDA: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal Infections |
| September 5 |
Phase Forward Acquires Clarix LLC, Innovation Leader in Web-Integrated Interactive Response Technology (IRT) for Clinical Trials |
| September 5 |
Free Drug Samples May End Up Costing Uninsured More |
| September 5 |
Inauguration of the Sanofi-Aventis Central Anti-Counterfeit Laboratory in Tours |
| September 5 |
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers |
| September 5 |
Reps. Dingell, Stupak Write Schering-Plough and Merck on Vytorin-Cancer Link |
| September 5 |
Prescription Drug Advertising Subject of New FDA Web Site for Consumers |
| September 5 |
FDA to Post Quarterly Report of Potential Safety Issues |
| September 8 |
New Low-Dose Oral Contraceptive Yaz Launched in Europe |
| September 8 |
FDA Issues Warning Letter for Forest Laboratories' Bystolic Tablets |
| September 8 |
GlaxoSmithKline plc - Directorate Change |
| September 9 |
Pharmas Challenged by Product Risk and Philanthropy Fatigue |
| September 9 |
Pharmas Challenged by Product Risk and Philanthropy Fatigue |
| September 9 |
SDI Reports: Prescribers May Influence Patient Adherence by Authorizing More Refills |
| September 9 |
Federal Court of Appeals in a Divided Decision Reverses District Court Ruling Dismissing Vioxx Securities Class Action |
| September 9 |
Solvay Pharmaceuticals Acquires Innogenetics |
| September 10 |
Prologue Acquisition Update and Termination of Linkcon Business Combination |
| September 10 |
Sanofi-Aventis: Upcoming Change of Chief Executive Officer |
| September 10 |
ImClone Systems Issues Statement |
| September 11 |
Cell Genesys Reconfirms Plans with FDA for Phase 3 Program for GVAX Immunotherapy While on Partial Clinical Hold |
| September 11 |
King to Commence Cash Tender Offer for Alpharma at $37 Per Share |
| September 11 |
Bristol-Myers Squibb Submits Letter to ImClone Board of Directors |
| September 11 |
Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked |
| September 11 |
FDA MedWatch- Rituxan (rituximab)- Important New Safety Information Regarding Progressive Multifocal Leukoencephalopathy With The Use Of Rituxan |
| September 11 |
Alpharma Urges Shareholders to Take No Action with Respect to King Pharmaceuticals' Announced Intent to Commence a Tender Offer |
| September 12 |
ARIAD Announces Merger with ARIAD Gene Therapeutics, Inc. |
| September 12 |
ImClone Systems Submits Letter to Bristol-Myers Squibb |
| September 12 |
King Commences Cash Tender Offer for Alpharma at $37 Per Share |
| September 12 |
NACDS 2008 Chain Pharmacy Industry Profile Showcases Extraordinary Impact of Pharmacies as a Frontline Healthcare Provider, Significantly Impacting Economy |
| September 15 |
WebMD to Acquire QualityHealth.com |
| September 15 |
Betaseron to Offer the Thinnest Needle in Multiple Sclerosis |
| September 15 |
Online Video is an Emerging Channel for Physicians to Connect with Pharmaceutical Companies |
| September 15 |
Newer Antipsychotics No Better Than Older Drug in Treating Child and Adolescent Schizophrenia |
| September 15 |
SeraCare Life Sciences Announces Completion of SEC Investigation |
| September 15 |
Teva Announces Appellate Court Reverses Generic Risperdal Exclusivity Decision |
| September 15 |
Pfizer Launches New Medicine Safety Website to Help Healthcare Professionals and Patients Make Better Informed Decisions about Treatment Options |
| September 15 |
Cybercitizen Health Europe Study Reveals How European Consumers Use the Internet for Health Information |
| September 16 |
Charles River Acquires MIR Preclinical Services |
| September 16 |
Bayer HealthCare Acquires German DIREVO Biotech AG |
| September 16 |
GSK and XenoPort Announce Submission of NDA Requesting FDA Approval of Solzira for Restless Legs Syndrome |
| September 16 |
MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy |
| September 16 |
Cytokinetics Announces Strategic Realignment of Workforce and Operations |
| September 17 |
FDA Issues Warning Letters to Ranbaxy Laboratories Ltd., and an Import Alert for Drugs from Two Ranbaxy Plants in India |
| September 17 |
Biovail Acquires Prestwick Pharmaceuticals |
| September 17 |
ViRexx Announces Failure to Secure an Alternative Equivalent Funder to Replace LM Funds Corp. |
| September 17 |
Information on the Removal From Office of Mr. Gerard Le Fur and the Appointment of Mr. Chris Viehbacher as Chief Executive Officer |
| September 17 |
Ranbaxy, Statement on FDA Letters |
| September 17 |
André Hoffmann Acquires Expanded Position in MedAssurant and Joins Board of Directors |
| September 18 |
Neose Technologies to Sell its Assets to Novo Nordisk and BioGeneriX |
| September 18 |
Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa |
| September 18 |
Ranbaxy Laboratories, Ltd., Retains Former New York City Mayor Rudy Giuliani to Lead Team in Resolution of Issues Raised by U. S. Food & Drug Administration |
| September 18 |
SCT Receives Letter From Health Canada and Verbal Request From FDA to Place a Clinical Hold on Its REGENESIS Phase IIb Stroke Trial |
| September 19 |
Erbitux Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer |
| September 19 |
Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation |
| September 19 |
FDA Drug Safety Newsletter: Postmarketing Reviews |
| September 22 |
Encorium Announces the Initiation of a Strategic Partnership With Prologue Research |
| September 22 |
Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials |
| September 22 |
Angiotech Announces Reorganization and Cost Reduction Initiatives, Updates Financial Outlook |
| September 22 |
Med Ad News Names Novartis Pharmaceutical Company of the Year |
| September 22 |
AstraZeneca Receives Six Months Pediatric Exclusivity for Casodex (bicalutamide) from the FDA |
| September 22 |
Proposed Class Action Settlement and Class Certification Regarding Wholesale Drug Pricing May Affect Consumers and Third-Party Payors |
| September 23 |
Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share |
| September 23 |
Half of Trials Supporting FDA Applications Go Unpublished |
| September 23 |
FDA MedWatch - Tarceva (erlotinib) - Cases of Hepatic Failure and Hepatorenal Syndrome, Including Fatalities, Have Been Reported During Use of Tarceva |
| September 23 |
Icahn Responds to Cornelius |
| September 24 |
FDA Warns Companies to Stop Marketing Unapproved Ophthalmic Balanced Salt Solution Drug Products and Topical Drug Products Containing Papain |
| September 24 |
Roche Completes Acquisition of ARIUS |
| September 24 |
Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments |
| September 24 |
Elias A. Zerhouni to End Tenure as Director of the National Institutes of Health |
| September 25 |
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company |
| September 25 |
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds |
| September 25 |
Medicis Announces Intent to Restate Financial Statements |
| September 25 |
NICE Guidelines are Set to Improve Care and Management of Children, Young People and Adults With ADHD |
| September 25 |
Canon Communications’ R&D Directions Magazine Wins Bronze Eddie Award |
| September 25 |
AARP Rx Watchdog Report Finds Specialty Drug Prices Soar |
| September 26 |
Alpharma Board of Directors Unanimously Rejects King Pharmaceuticals' Unsolicited Tender Offer as "Financially Inadequate" |
| September 26 |
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe |
| September 26 |
Online European Consumers Turn to Search Engines and Wikipedia for Health Information |
| September 26 |
Crucell's Swiss Affiliate Berna Biotech to Cease All Animal Testing |
| September 26 |
FDA MedWatch - Epoetin alfa- Preliminary Safety Findings Show More Deaths In Patients Given Epoetin-alpha Versus Placebo |
| September 29 |
Cardinal Health Plans to Spin Off Clinical and Medical Products Businesses, Creating Global Leader in Medical Technology |
| September 29 |
WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China |
| September 29 |
FDA Issues Several Letters for ADHD Drugs |
| September 29 |
FDA Continues to Review Prasugrel New Drug Application |
| September 29 |
ImClone Systems Issues Statement |
| September 29 |
FDA Grants Lilly's Alimta (Pemetrexed for Injection) Third U.S. Approval |
| September 29 |
ImClone Systems Issues Statement |
| September 29 |
Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices |
